EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieVergleichsstudieOpen Access

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Benjamin J Solomon iD, Geoffrey Liu iD, Enriqueta Felip iD, Tony S K Mok iD, Ross A Soo iD, Julien Mazieres iD, Alice T Shaw iD, Filippo de Marinis, Yasushi Goto iD, Yi-Long Wu iD, Dong-Wan Kim iD, Jean-François Martini iD und 6 weitere

Journal of Clinical Oncology · 10.10.2024 · 42 (29) · 3400-3409

DOI: 10.1200/jco.24.00581 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.10.2024. Verfasst von Benjamin J Solomon und 17 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lactams, Lung Neoplasms, Crizotinib. Die Arbeit wurde bisher 394-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung cancer (NSCLC) in the phase III CROWN study. Here, we report long-term outcomes from CROWN after 5 years of follow-up. METHODS Two hundred ninety-six patients with ALK -positive NSCLC were randomly assigned 1:1 to receive lorlatinib 100 mg once daily (n = 149) or crizotinib 250 mg twice daily (n = 147). This post hoc analysis presents updated investigator-assessed efficacy outcomes, safety, and biomarker analyses. RESULTS With a median follow-up for PFS of 60.2 and 55.1 months, respectively, median PFS was not reached (NR [95% CI, 64.3 to NR]) with lorlatinib and 9.1 months (95% CI, 7.4 to 10.9) with crizotinib (hazard ratio [HR], 0.19 [95% CI, 0.13 to 0.27]); 5-year PFS was 60% (95% CI, 51 to 68) and 8% (95% CI, 3 to 14), respectively. Median time to intracranial progression was NR (95% CI, NR to NR) with lorlatinib and 16.4 months (95% CI, 12.7 to 21.9) with crizotinib (HR, 0.06 [95% CI, 0.03 to 0.12]). Safety profile was consistent with that in prior analyses. Emerging new ALK resistance mutations were not detected in circulating tumor DNA collected at the end of lorlatinib treatment. CONCLUSION After 5 years of follow-up, median PFS has yet to be reached in the lorlatinib group, corresponding to the longest PFS ever reported with any single-agent molecular targeted treatment in advanced NSCLC and across all metastatic solid tumors. These results coupled with prolonged intracranial efficacy and absence of new safety signals represent an unprecedented outcome for patients with advanced ALK -positive NSCLC and set a new benchmark for targeted therapies in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLactamsLung NeoplasmsCrizotinibAminopyridinesAnaplastic Lymphoma KinasePyrazolesLactams, MacrocyclicHumansFemaleMaleMiddle AgedAgedAdultProgression-Free SurvivalProtein Kinase Inhibitors

Substanzen

LactamslorlatinibCrizotinibAminopyridinesAnaplastic Lymphoma KinasePyrazolesLactams, MacrocyclicALK protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong Special Administrative Region of China, China.
  • National University Cancer Institute, Singapore.
  • Pulmonology Department, Toulouse University Hospital and Centre de Recherche Cancérologie Toulouse CRCT, INSERM, France.

ORCID-Profile: Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, Tony S K Mok, Ross A Soo, Julien Mazieres, Alice T Shaw, Yasushi Goto, Yi-Long Wu, Dong-Wan Kim, Jean-François Martini, Francesca Toffalorio, Todd M Bauer

Zitieren

APA

Solomon, B. J., Liu, G., Felip, E., Mok, T. S. K., Soo, R. A., Mazieres, J., Shaw, A. T., de Marinis, F., Goto, Y., Wu, Y. L., Kim, D. W., Martini, J. F., Messina, R., Paolini, J., Polli, A., Thomaidou, D., Toffalorio, F., & Bauer, T. M. (2024). Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of Clinical Oncology, 42(29), 3400-3409. https://doi.org/10.1200/jco.24.00581

Vancouver

Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of Clinical Oncology. 2024;42(29):3400-3409. doi:10.1200/jco.24.00581

BibTeX
@article{Solomon2024,
  author = {Solomon, Benjamin J and Liu, Geoffrey and Felip, Enriqueta and Mok, Tony S K and Soo, Ross A and Mazieres, Julien and Shaw, Alice T and de Marinis, Filippo and Goto, Yasushi and Wu, Yi-Long and Kim, Dong-Wan and Martini, Jean-François and Messina, Rossella and Paolini, Jolanda and Polli, Anna and Thomaidou, Despina and Toffalorio, Francesca and Bauer, Todd M},
  title = {Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {29},
  pages = {3400--3409},
  doi = {10.1200/jco.24.00581}
}
Kostenlos starten →